75 / 89
75
phenomenon secondary to systemic sclerosis. A
multicenter, placebo-controlled, double-blind
study. Ann Intern Med 1994;120:199-206.
62.
Wigley FM, Korn JH, Csuka ME, Medsger TA Jr,
Rothfield NF, Ellman M, et al. Oral iloprost
treatment
in
patients
with
Raynaud's
phenomenon secondary to systemic sclerosis: a
multicenter, placebo-controlled, double-blind
study. Arthritis Rheum 1998; 41: 670-7.
63.
Scorza R, Caronni M, Mascagni B, Berruti V,
Bazzi S, Micallef E, et al. Effects of long-term
cyclic iloprost therapy in systemic sclerosis with
Raynaud's phenomenon. A randomized,
controlled study. Clin Exp Rheumatol
2001;19:503-8.
64.
Rademaker M, Cooke ED, Almond NE,
Beacham JA, Smith RE, Mant TG, et al
Comparison of intravenous infusions of iloprost
and oral nifedipine in treatment of Raynaud's
phenomenon in patients with systemic sclerosis:
a double blind randomised study. BMJ
1989;298:561-4.
65.
Pope J, Fenlon D, Thompson A, Shea B, Furst D,
Wells G, et al. Prazosin for Raynaud's
phenomenon in progressive systemic sclerosis.
Cochrane Database Syst Rev 2000;(2):CD000956.
66.
Surwit RS, Gilgor RS, Allen LM, Duvic M. A
double-blind study of prazosin in the treatment
of Raynaud's phenomenon in scleroderma. Arch
Dermatol 1984;120:329-31.